$GALT News

GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH

Galectin De-Risks Belapectin Path With FDA Alignment - Sets Stage For Phase 3 Upside

GALT Stock Surges 22% — On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial

HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target

Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension

Galectin Therapeutics Announces Positive Feedback From Recent In Person Type C Meeting With FDA For Its Belapectin To Treat Patients With Metabolic Dysfunction-associated Steatohepatitis Cirrhosis, Portal Hypertension

Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis

Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update

Galectin Therapeutics Q1 EPS $(0.08) Misses $(0.06) Estimate

Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology

Galectin Therapeutics Announces Publication Of Results From NAVIGATE Phase 2b Clinical Trial Evaluating Belapectin In Patients With MASH Cirrhosis And Portal Hypertension In AASLD Flagship Journal Hepatology

Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock?

Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update

Galectin Therapeutics Q4 EPS $(0.08) Beats $(0.11) Estimate

Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.

Galectin Therapeutics Highlights Belapectin Data in MASH Cirrhosis KOL Event, Eyes Next Steps

Galectin Therapeutics Option Alert: Jul 17 $5 Calls at the Ask: 3575 @ $0.45 vs 3177 OI; Earnings 3/30 Before Open [est] Ref=$3.015

Galectin Therapeutics Inc. (GALT) Discusses Updated Results for Belapectin in Treatment of MASH Cirrhosis and Portal Hypertension Transcript

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET

Galectin Therapeutics To Host Virtual KOL Event On March 10, Focusing On Unmet Need And Current Treatment Landscape For MASH Cirrhosis And Portal Hypertension